In a bid to navigate the swirling waters of geopolitical uncertainties and mounting drug pricing pressures, Genentech, a San Francisco-based biotech heavyweight, is making a strategic pivot towards bolstering its domestic manufacturing capabilities. This move, propelled by the current administration’s emphasis on homegrown production, is indicative of an industry-wide shift towards onshoring, as companies look to reduce their dependency on international partners and respond more effectively to the evolving political and economic landscape.
Genentech’s decision to ramp up its US-based production comes at a time when the industry is witnessing a surge in domestic contract service agreements, a trend underscored by the GlobalData’s Deals Database. In Q1 2025 alone, there was a noticeable uptick in such agreements compared to the previous year, despite witnessing a downward trajectory over the past five years.
At the heart of Genentech’s strategy is a whopping $700 million investment to establish its maiden manufacturing facility on the East Coast, specifically in Holly Springs, North Carolina. Spread across an expanse of 700,000 square feet, this new facility is poised to create a significant economic ripple effect in the region, with more than 1,500 construction jobs and over 400 permanent manufacturing positions on the cards.
But this is just the tip of the iceberg. Roche, Genentech’s parent company, has unveiled ambitious plans to pump $50 billion into pharmaceuticals and diagnostics in the US over the next half-decade. From Indiana to Pennsylvania, Massachusetts to California, this colossal investment will fuel the expansion of new and existing manufacturing facilities across the country, thereby underpinning Roche’s robust Q1 2025 earnings.
Yet, this onshoring trend isn’t just a product of policy inclination. It’s a strategic response to a host of challenges, from international tariffs and national security concerns to rising tensions with China. The initial days of Trump’s second tenure saw several executive orders that significantly impacted the pharmaceutical industry, sparking a marked increase in outsourcing agreements with domestic manufacturers.
However, the industry’s response to the Trump administration’s “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” executive order is far from unanimous. Roche has hinted at reassessing its $50 billion manufacturing investment in response to potential policy fluctuations. The order, which seeks to align US drug prices with the lowest prices in other developed nations, has stirred up a debate among pharmaceutical companies and stakeholders, with PhRMA president Stephen Ubl warning that the plan could jeopardize the planned investments in America.
As Genentech and Roche navigate these intricate dynamics, their strategic shifts underscore the pharmaceutical industry’s resilience and adaptability in the face of change. It’s a testament to the industry’s relentless pursuit of innovation, a pursuit that is visibly reshaping the manufacturing landscape and setting the stage for what promises to be a defining decade for biotech.
Read more from pharmaceutical-technology.com